The $300M shelf is a standard precautionary filing for a clinical-stage biotech with a $325M market cap. No immediate dilution risk, the company has $132.6M cash and explicitly states it is funded through Phase 2 readouts. Monitor for any prospectus supplement filing, which would signal an actual offering. The concurrent positive Phase 1b data and upcoming Phase 2 catalysts (UC IND in Q2 2026, Phase 2 start in Q3 2026) provide a potential positive narrative that could support the stock if no offering materializes.
PALI drugs
PALI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $1.87entry
- T+1 · 6mo ago 0.00%α +0.00% · $1.87
- T+5 · 6mo ago −3.21%α −2.05% · $1.81
- T+20 · 5mo ago −4.81%α −4.20% · $1.78
- T+60 · 3mo ago +12.83%α +8.40% · $2.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palisade Bio filed a $300M universal shelf registration statement on Form S-3, concurrent with its Q1 2026 earnings release and 10-Q filing. The company reported $132.6M in cash as of March 31, 2026, with R&D expenses of $6.4M (up from $1.0M YoY) and a net loss of $9.6M. The shelf provides maximum flexibility for future capital raises, but the company states existing cash funds operations through key Phase 2 readouts in 2H 2027 and early 2028, suggesting this is an opportunistic shelf filing rather than an imminent dilutive event.
Key Financial Metrics
Key Facts
- Filed $300M universal shelf registration (S-3) on May 12, 2026
- Cash and cash equivalents of $132.6M as of March 31, 2026
- Q1 2026 R&D expenses of $6.4M vs $1.0M in Q1 2025 (up 540%)
- Q1 2026 net loss of $9.6M vs $2.4M in Q1 2025
- Company states cash on hand sufficient through Phase 2 UC readout (2H 2027) and Phase 2 CD readout (early 2028)
- Phase 2 UC trial initiation targeted for Q3 2026; IND submission expected Q2 2026
- Phase 1a/b for PALI-2108 completed with positive data in UC and fibrostenotic Crohn's disease
- Outstanding warrants to purchase ~13.95M shares at $2.45 weighted-average exercise price
- Pre-funded warrants to purchase ~43.87M shares at $0.0001 exercise price
- Stock price at filing: $1.94 per share (May 11, 2026)
Financial Impact
Up to $300M in potential future capital raises, but no immediate offering. Current cash burn rate ~$38.4M annualized (Q1 2026 operating expenses).
Risk Factors
- Shelf allows for up to $300M in future dilution at management's discretion
- Q1 2026 operating loss of $9.6M with R&D spend accelerating 5.4x YoY
- Pre-funded warrants (43.87M shares at $0.0001) represent significant overhang, exercisable at any time
- Phase 2 clinical risk, PALI-2108 has only been tested in 89 subjects across Phase 1
- No revenue and no approved products, entirely dependent on clinical success and capital markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-022548 |
| Exhibit: ex4-5.htm | 0001493152-26-022548 |
Track record
14 reports on PALI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $1.17 Now $1.03 −11.97% settles Dec 10
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
- Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers